ヴェネトクラックスとアザシチジンで治療された急性骨髄性白血病における14日目の測定可能な残留疾患の予後値
Jiaying Lian1,2, Xianxu Zhuang1,2, Ying Chen1,2
1Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Cancer
|August 26, 2025
まとめ
急性骨髄性白血病 (AML) のヴェネトクラックスとアザシチジン治療後の14日目の測定可能な残留疾患 (MRD) のモニタリングは生存率を予測することができます. MRDの陰性化がよりよい結果につながり,MRDの陽性化を持つ人にとって,移植は生存率を向上させる可能性があります.
科学分野:
- 血液学
- 腫瘍学
- 臨床研究
背景:
- アザシチジン (AZA) と併用したヴェネトクラックス (VEN) は,急性骨髄性白血病 (AML) の治療法です.
- AMLにおけるVEN- AZA治療の予後要因は,まだ十分に研究されていない.
- VEN- AZAで治療されたAML患者の測定可能な残留疾患 (MRD) のモニタリングの臨床的有用性に関する証拠は限られている.
研究 の 目的:
- 生存率を予測するMRDの役割とタイミングを検証する.
- AML患者のVEN- AZA治療後の14日のMRDの予後値を分析する.
主な方法:
- VEN- AZAで治療された75人の新規診断AML患者の遡及分析.
- 14日MRD値に基づいて患者の分類:MRD陽性 (> 1%) とMRD陰性 (≤ 1%).
- 総生存率 (OS) とイベントフリー生存率 (EFS) の評価は,MRD状態と他の要因に関連しています.
主要な成果:
- 14日のMRDの陰性値は,OSの改善 (p=0. 024) とEFSの改善 (p=0. 044) と関連付けられました.
- MRDの陰性,CSF3Rの陰性,移植は生存率の改善の重要な予測因子でした.
- 移植を受けたMRD陽性患者は,より長いOSとEFSの傾向を示しました.
結論:
- VEN- AZAで治療されたAML患者では,14日MRDの陰性化が好ましい予後指標である.
- CSF3Rの陰性と移植は,AMLのより良い予後に関連しています.
- VEN- AZAで治療されたMRD陽性AML患者の生存率が向上する可能性があります.
さらに関連する動画
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.1K
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
261
関連する概念動画
Blood Transfusion and Agglutination
13.1K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.1K
Bone Marrow Sampling and Transplants
3.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.1K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
582
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
582
